Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC.
暂无分享,去创建一个
Jing Wang | J. Roth | J. Lee | S. Swisher | D. Gibbons | V. Papadimitrakopoulou | H. Tran | L. Diao | Jianjun Zhang | R. Lanman | Carol C. Wu | V. Raymond | V. Lam | W. Rinsurongkawong | Lerong Li | J. Lewis | J. Heymach | Emily B. Roarty | J. Lee
[1] X. Yi,et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer , 2020, Cell Death & Disease.
[2] D. Ledbetter,et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention , 2020, Science.
[3] Edward S. Kim,et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.
[4] D. Berry,et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E. Helman,et al. Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.
[6] Ash A. Alizadeh,et al. A mathematical model of ctDNA shedding predicts tumor detection size , 2020, Science Advances.
[7] Harry J de Koning,et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.
[8] A. Hackshaw,et al. P1.11-19 Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test , 2019, Journal of Thoracic Oncology.
[9] J. Ptak,et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. , 2019, JAMA oncology.
[10] Ying Cheng,et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. , 2019, Journal of Clinical Oncology.
[11] S. Shchegrova,et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.
[12] R. Scharpf,et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. , 2019, Cancer research.
[13] Sharyn I. Katz,et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.
[14] R. Scharpf,et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2018, Cancer research.
[15] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Roth,et al. MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer , 2018, Journal of Thoracic Oncology.
[17] A. Gupta,et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.
[18] Jacob Silterra,et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.
[19] Joon-Oh Park,et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.
[20] C. Paweletz,et al. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.
[21] Ash A. Alizadeh,et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.
[22] Maximilian Diehn,et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.
[23] S. Morbelli,et al. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18F-FDG PET/CT Study , 2017, The Journal of Nuclear Medicine.
[24] Ashwini Naik,et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.
[25] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[26] H. Ye,et al. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing , 2016, Scientific Reports.
[27] Suzanne E Dahlberg,et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.
[28] S. Mortimer,et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .
[29] Chandra Sekhar Pedamallu,et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.
[30] B. Kermani,et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.
[31] Jorge S. Reis-Filho,et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.
[32] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[33] Kyoungjune Pak,et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[34] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Vadgama,et al. The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients , 2013, International journal of molecular sciences.
[36] T. Mitsudomi,et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] John L. Humm,et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[38] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[39] W. El-Deiry,et al. Clinical implications of p53 mutations in lung cancer. , 2003, Methods in molecular medicine.